Brainstorm Cell Therapeutics Inc Total Assets
Brainstorm Cell Therapeutics Inc total assets. Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) holds total assets worth $472.00K USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Brainstorm Cell Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Brainstorm Cell Therapeutics Inc (2001–2025)
Total assets of Brainstorm Cell Therapeutics Inc from 2001 to 2025. This chart illustrates how Brainstorm Cell Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Brainstorm Cell Therapeutics Inc for real-time trading data and today's change.
Brainstorm Cell Therapeutics Inc - Asset Composition Analysis
Brainstorm Cell Therapeutics Inc Total Assets Breakdown (December 2025)
Brainstorm Cell Therapeutics Inc total assets breakdown as of December 2025. Brainstorm Cell Therapeutics Inc's total assets of $472.00K consist of 42.9% current assets and 57.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.1% |
| Accounts Receivable | $86.00K | 12.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Brainstorm Cell Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BCLI current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Brainstorm Cell Therapeutics Inc's current assets represent 42.9% of total assets in 2025, a decrease from 58.0% in 2001.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 56.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 42.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 12.0% of total assets.
Brainstorm Cell Therapeutics Inc Competitors by Total Assets
Key competitors of Brainstorm Cell Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Brainstorm Cell Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.18 | 4.78 |
| Quick Ratio | 0.03 | 0.18 | 4.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.07 Million | $-7.01 Million | $22.10 Million |
Brainstorm Cell Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Brainstorm Cell Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 54.50 |
| Latest Market Cap to Assets Ratio | 16.40 |
| Asset Growth Rate (YoY) | -61.0% |
| Total Assets | $715.00K |
| Market Capitalization | $11.73 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Brainstorm Cell Therapeutics Inc's assets at a significant premium (16.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Brainstorm Cell Therapeutics Inc's assets decreased by 61.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Brainstorm Cell Therapeutics Inc (2001–2025)
The table below shows the annual total assets of Brainstorm Cell Therapeutics Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $715.00K | -60.97% |
| 2024-12-31 | $1.83 Million | -56.46% |
| 2023-12-31 | $4.21 Million | -50.21% |
| 2022-12-31 | $8.45 Million | -71.13% |
| 2021-12-31 | $29.28 Million | -42.88% |
| 2020-12-31 | $51.26 Million | +684.50% |
| 2019-12-31 | $6.53 Million | -41.81% |
| 2018-12-31 | $11.23 Million | -1.71% |
| 2017-12-31 | $11.42 Million | +6.10% |
| 2016-12-31 | $10.77 Million | -36.97% |
| 2015-12-31 | $17.08 Million | +72.33% |
| 2014-12-31 | $9.91 Million | +109.71% |
| 2013-12-31 | $4.73 Million | -11.00% |
| 2012-12-31 | $5.31 Million | +93.51% |
| 2011-12-31 | $2.74 Million | +151.97% |
| 2010-12-31 | $1.09 Million | +43.86% |
| 2009-12-31 | $757.00K | -13.49% |
| 2008-12-31 | $875.00K | -19.21% |
| 2007-12-31 | $1.08 Million | +49.92% |
| 2006-12-31 | $722.37K | -15.99% |
| 2005-12-31 | $859.81K | -2.23% |
| 2004-12-31 | $879.40K | +5318.39% |
| 2003-12-31 | $16.23K | -64.32% |
| 2002-12-31 | $45.49K | -28.54% |
| 2001-12-31 | $63.65K | -- |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modul… Read more